RZ-001
Phase 2An RNA-based cancer gene therapy in a Phase 1b/2a trial for hepatocellular carcinoma and a Phase 1/2a trial for glioblastoma, with US FDA RMAT designation.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Has licensed its platform to Lilly and released early clinical data for RZ-001 in liver cancer and glioblastoma.
Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing
A biotech company developing cancer and genetic-disease therapies on its trans-splicing ribozyme RNA editing and correction platform.
An RNA-based cancer gene therapy in a Phase 1b/2a trial for hepatocellular carcinoma and a Phase 1/2a trial for glioblastoma, with US FDA RMAT designation.
Its trans-splicing ribozyme platform underpins an RNA editing therapy for hereditary hearing loss with Eli Lilly; Rznomics runs early research.
An Alzheimer's disease candidate under evaluation with a global pharma company through a material transfer agreement.
Presented interim combination-trial results for RZ-001 in hepatocellular carcinoma orally at AACR 2026.
Listed on the KOSDAQ market.
Signed a global licence agreement with Eli Lilly for an RNA editing therapy for hereditary hearing loss.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.